» Articles » PMID: 20023246

Clinical Application of Autologous Three-cellular Cultured Skin Substitutes Based on Esterified Hyaluronic Acid Scaffold: Our Experience

Overview
Journal In Vivo
Specialty Oncology
Date 2009 Dec 22
PMID 20023246
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The aim of this work was to present our experience in the use of autologous three-cellular cultured skin substitutes (CSS). This method represents a surgical alternative in the treatment of a variety of pathologies, including burns, ulcers, giant nevi and tumors.

Patients And Methods: CSS were obtained from full-thickness skin biopsies collected after enrolment of 11 patients in a clinical trial protocol approved by the local Institutional Review Boards of the 'La Sapienza' University of Rome and registered in clinicaltrials.gov (ID: NCT00718978). CSS consisted of a structure made by a pluristratified epithelial cell surface with melanocytes (ratio 1/20) and a basement of fibroblasts kept together by an esterified hyaluronic acid scaffold that can be surgically manipulated and is gradually reabsorbed after implantation and substituted by the host connectival stroma.

Results: At the time of withdrawal of medication, the graft take was comparable to that of autografts, whereas in the follow-up visits, loss of the epithelial layer varied markedly (from 5 to 70%) while fibroblast cellular component growth prevailed. In one patient, there was complete dermal-epidermal construct survival.

Conclusion: Given the anatomical complexity of the skin, we still have a long way to go before we are able to recreate all the cellular and structural characteristics of this organ. Results are, however, gradually improving, as is demonstrated by a successful graft, which was histologically shown to have a three-dimensional structure that maintained its conformation in vivo (epithelium, basement membrane, dermis, subcutis) in one patient. The take of melanocytes improved the final esthetic outcome.

Citing Articles

Effect of Fibroblast Growth Factor-2 on Melanocyte Proliferation in Tissue-Engineered Skin Substitutes.

Ferland K, Magne B, De Koninck H, Barbier M, Larouche D, Germain L Int J Mol Sci. 2025; 26(4).

PMID: 40004167 PMC: 11855325. DOI: 10.3390/ijms26041704.


A comprehensive evaluation of dermal fibroblast therapy in clinical trials for treating skin disorders and cosmetic applications: a scoping review.

Rahnama M, Ghasemzadeh N, Ebrahimi Y, Golchin A Stem Cell Res Ther. 2024; 15(1):318.

PMID: 39304949 PMC: 11416016. DOI: 10.1186/s13287-024-03892-0.


Cellular human tissue-engineered skin substitutes investigated for deep and difficult to heal injuries.

Sierra-Sanchez A, Kim K, Blasco-Morente G, Arias-Santiago S NPJ Regen Med. 2021; 6(1):35.

PMID: 34140525 PMC: 8211795. DOI: 10.1038/s41536-021-00144-0.


Current Approaches Targeting the Wound Healing Phases to Attenuate Fibrosis and Scarring.

El Ayadi A, Jay J, Prasai A Int J Mol Sci. 2020; 21(3).

PMID: 32046094 PMC: 7037118. DOI: 10.3390/ijms21031105.


Growth Factors Delivery System for Skin Regeneration: An Advanced Wound Dressing.

Nardini M, Perteghella S, Mastracci L, Grillo F, Marrubini G, Bari E Pharmaceutics. 2020; 12(2).

PMID: 32028579 PMC: 7076531. DOI: 10.3390/pharmaceutics12020120.